IP Library Granted Patent US 7,455,698
Granted Patent B2
US 7,455,698 · App. 11/568,865 · Granted Nov 25, 2008

Cationic dyes and dyestuff for keratin fibres containing said compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,698
App. No.
11/568,865
Granted
Nov 25, 2008
Kind
B2
Abstract

4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salts of the general formula(I) and colorants comprising these compounds for keratin fibres.

Claims (27)

1. 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt of the general formula (I)

in which

R1 is a C 1 -C 6 -alkyl group, a C 1 -C 4 -hydroxyalkyl group, a C 2 -C 4 -dihydroxyalkyl group or a C 2 -C 6 -alkoxy-(C 1 -C 2 )-alkyl group, a phenyl group, a benzyl group or a substituted benzyl group;

R3 and R4, independently of one another, are hydrogen, a C 1 -C 6 -alkyl group, a C 1 -C 4 -hydroxyalkyl group, a C 2 -C 4 -dihydroxyalkyl group or a C 1 -C 4 -alkoxy-(C 1 -C 4 )alkyl group, or

R3 and R4 together form a four-membered to eight-membered aliphatic ring;

R2 and R6, independently of one another, are hydrogen, a C 1 -C 4 -alkyl group, a C 1 -C 4 -hydroxyalkyl group, a phenyl group, a substituted phenyl group, a halogen atom or a substituted aminomethyl group;

R5 is a cyano group, a —NR10C(O)R11 group or a sulphonamide group;

R7 and R8, independently of one another, are a C 1 -C 6 -alkyl group, an unsaturated C 3 -C 6 -alkyl group, a C 2 -C 4 -hydroxyalkyl group, a C 3 -C 4 -dihydroxyalkyl group, a C 2 -C 4 -aminoalkyl group, a C 2 -C 4 -dimethylaminoalkyl group, a C 2 -C 4 -acetylaminoalkyl group, a C 2 -C 4 -methoxyalkyl group, a C 2 -C 4 -ethoxyalkyl group, a C 1 -C 4 -cyanoalkyl group, a C 1 -C 4 -carboxyalkyl group or a C 1 -C 4 -aminocarbonylalkyl group, or

R7 and R8, together with the nitrogen atom, form a ring of the formula

R9 is hydrogen or one or more hydroxyl groups, carboxyl groups, aminocarbonyl groups or hydroxymethyl groups;

R10 is hydrogen or a C 1 -C 6 -alkyl group;

R11 is hydrogen, a C 1 -C 6 -alkyl group, an amino group, an alkylamino group, a dialkylamino group, a phenyl group or a substituted phenyl group; and

X − is an anion.

2. 4 (Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt according to claim 1 , characterized in that one or more of the radicals R2, R3, R4 and R6 are hydrogen.

3. 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt according to claim 1 , characterized in that R1 is a C 1 -C 6 -alkyl group, a C 1 -C 4 -hydroxyalkyl group, a benzyl group or methylbenzyl group and R2, R3, R4 and R6 are hydrogen at the same time.

4. 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt according to claim 1 , characterized in that R5 is an amino group, a —NHC (O)R11 group or a sulphonamide group and R6 is hydrogen.

5. 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt according to claim 1 , characterized in that, in the formula(I), the radicals R7 and R8 are a C 1 -C 3 -alkyl group —in particular a methyl group — or, together with the nitrogen atom, form a pyrrolidine ring.

6. 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium according to claim 1 , characterized in that it is chosen from(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)di(2-hydroxyethyl)ammonium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene )-4-(hydroxymethyl) -piperidinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol -4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)hydroxymethyl -pyrrolidinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol -4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-4-hydroxypiperidinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, (4-(5-amino-1-(2-hydroxyethyl)-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)morpholinium, 1-(4-(5-amino-l-(2-hydroxyethyl) -1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)piperidinium, 1-(4-(5-amino-l-(2-hydroxyethyl) -1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)pyrrolidinium, (4-(5-amino-l-(2-hydroxyethyl) -1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)di(2-hydroxyethyl)ammonium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H -pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)hydroxymethylpiperidnium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)hydroxymethylpyrroldinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-3-hydroxypiperidinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, 4-(4-(5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-ylimino)-3-methylsulphon -amidocyclohexa-2,5-dienylidene)morpholinium, 1-(4-(5-amino -1-(2hydroxyethyl)-1-H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)piperidinium, 1-(4-(5-amino-1-(2-hydroxyethyl)-1-H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)pyrrolidinium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino) -3-ureidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)di(2-hydroxy-ethyl)ammonium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-4-(hydroxymethyl)piperidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-(hydroxymethyl)pyrrolidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4ylimino)-3-ureidocyclohexa-2,5-dienylidene)-4-hydroxypiperidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, 4-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)morpholinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)piperidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)pyrrolidinium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)di(2-hydroxyethyl)ammonium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methyl -sulphonamidocyclohexa-2,5-dienylidene)hydroxymethyl -piperidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H -pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)hydroxymethylpyrrolidinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-4-hydroxypiperidinium, 1-(4-(5-amino-1-(4-methyl -phenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphon -amidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, (4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)morpholinium, 1-(4-(5-amino-1-(4-methylphenyl)methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)piperidinium, 1-(4-(5-amino-1-(4-methylphenyl) -methyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-pyrrolidinium, (4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)di(2-hydroxyethyl)ammonium, 1-(4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-4-(hydroxymethyl)piperidinium, 1-(4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-(hydroxymethyl)pyrrolidinium, 1-(4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-hydroxypiperidinium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, 4-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)morpholinium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)piperidinium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-ureidocyclohexa-2,5-dienylidene)pyrrolidinium, (4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)dimethylammonium, (4-(5-amino-1-isopropyl-1H -pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)diethylammonium, (4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)di(2-hydroxyethyl)ammonium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-4-(hydroxymethyl)piperidinium, 1-(4-(5amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-3-(hydroxymethyl)pyrrolidinium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-4-hydroxypiperidinium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-3-hydroxypyrrolidinium, 4-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)morpholinium, N-[(6-[(5-amino-1-isopropyl-1H-pyrazol-4-yl)imino]-3-(3-hydroxy-1-pyrrolidiniumylidene)-1,4-cyclohexadien-1-yl]urea, N-(-3-[(amino-carbonyl)amino]-4-{[5-amino-1-isopropyl-1H-pyrazol-4-yl]imino}-2,5-cyclohexadien-1-ylidene)-2-hydroxy-N-(2-hydroxyethyl)ethaneaminium, 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)-piperidinium and 1-(4-(5-amino-1-isopropyl-1H-pyrazol-4-ylimino)-3-methylsulphonamidocyclohexa-2,5-dienylidene)pyrrolidinium.

7. Agent for colouring keratin fibres, characterized in that it comprises at least one 4-(pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt of the formula(I) according to claim 1 .

8. Agent according to claim 7 , characterized in that it comprises the 4-(pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt of the formula(I) in an amount of from 0.005 to 20% by weight.

9. Agent according to claims 7 agent, characterized in that it additionally comprises at least one further direct natural or synthetic hair dye and/or at least one oxidation dye precursor.

10. Agent according to claim 9 , characterized in that the direct dyes are present in a total amount of from 0.001 to 4% by weight.

11. Agent according to claim 9 , characterized in that the oxidation dye precursors are present in a total amount of from 0.01 to 20% by weight.

12. Agent for the simultaneous lightening and colouring of keratin fibres containing at least one oxidizing agent, characterized in that it comprises at least one 4-(pyrazol-4-ylimino)-2,5-cyclohexadienylidene-ammonium salt of the formula (I) according to claim 1 .

13. Agent according to claim 12 , characterized in that it has a basic pH.

14. Agent according to claim 11 , characterized in that the oxidizing agent is hydrogen peroxide.

15. Agent according to claim 7 , characterized in that it is a hair colorant.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 055344 FRAME: 0422. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 29, 2021
From: HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND SÀRL
To: HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL
Reel/Frame 056712/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2021
From: HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SARL
To: WELLA INTERNATIONAL OPERATIONS SWITZERLAND SARL
Reel/Frame 055428/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND SÀRL
To: HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL
Reel/Frame 055344/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2016
From: WELLA GMBH
To: HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L
Reel/Frame 040420/0478 →